Per Walday
Vorstandsvorsitzender bei EXACT THERAPEUTICS
Vermögen: 1 833 $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Per Walday
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 19 | |
| Public Company | Biotechnology | 12 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Per Walday
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| AQUA BIO TECHNOLOGY ASA | Chemicals: Major Diversified | Director/Board Member Director/Board Member | |
| SHIRE | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| MEDIVIR AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Oxford | College/University | Corporate Officer/Principal Doctorate Degree | |
GE Healthcare AS
 GE Healthcare AS Medical SpecialtiesHealth Technology GE Healthcare AS markets contrast agent for x-ray, ultrasound, Magnetic Resonance Imaging, and radiopharmaceuticals for clinicians to predict, diagnose, inform, and treat diseases. The company was founded on September 07, 1981 and it is headquartered in Oslo, Norway. | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree | |
GE Healthcare Ltd. (United Kingdom)
 GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Medical Specialties | President Corporate Officer/Principal Corporate Officer/Principal | |
IoDP Medical Imaging Research
 IoDP Medical Imaging Research Miscellaneous Commercial ServicesCommercial Services Part of Thermo Fisher Scientific, Inc., IoDP Medical Imaging Research provides customized services for medical image analysis and image management in clinical trials to pharmaceutical and biotech companies, CROs, and public research organizations. The company is based in Sevres, France. IoDP Medical Imaging Research was acquired by Synexus Compass, Inc., part of Thermo Fisher Scientific, Inc. from September 03, 2019 on July 27, 2004. | Miscellaneous Commercial Services | Chief Executive Officer | |
| University of Stockholm | College/University | Masters Business Admin | |
| CALLIDITAS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ARCTICZYMES TECHNOLOGIES ASA | Medical Specialties | President Director/Board Member Director/Board Member | |
| WEIFA ASA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Royal Institute of Technology | College/University | Doctorate Degree | |
| University of Oslo | College/University | Doctorate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| Norwegian School of Economics & Business Administration | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree Graduate Degree | |
| University of Paris Jussieu | College/University | Undergraduate Degree | |
| NAVAMEDIC ASA | Medical Distributors | Director of Finance/CFO Director/Board Member | |
Center For Clinical & Basic Research
 Center For Clinical & Basic Research Miscellaneous Commercial ServicesCommercial Services Part of Thermo Fisher Scientific, Inc., Center For Clinical & Basic Research is a Danish company that provides radiology services. The company is based in Ballerup, Denmark. The company was founded by Claus Henrik Christiansen. Center For Clinical & Basic Research was acquired by Synexus Compass, Inc., part of Thermo Fisher Scientific, Inc. from September 03, 2019 on July 14, 2006. | Miscellaneous Commercial Services | Chief Executive Officer | |
| BI Norwegian Business School | College/University | Graduate Degree Graduate Degree | |
PricewaterhouseCoopers AS
 PricewaterhouseCoopers AS Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers AS provides audit, advisory, accounting, tax, and legal services. It offers its expertise to the following industries: bank and finance, energy, health, industry and commerce, oil and gas, public sector, real estate, shipping, and telecom and media. The company was founded by Olav Ildal in 1939 and is headquartered in Oslo, Norway. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor Director/Board Member | |
| BERGENBIO ASA | Pharmaceuticals: Major | Corporate Officer/Principal Chairman | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Chemlex AS | Director/Board Member | ||
| LANTHEUS HOLDINGS, INC. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chief Executive Officer | |
SpinChip Diagnostics AS
 SpinChip Diagnostics AS Electronic Equipment/InstrumentsElectronic Technology SpinChip Diagnostics AS develops a game changing and proprietary platform for in vitro diagnostics point of care analyses. Its point of care device will satisfy all key user requirements, both with respect to assaying performance and user-friendliness. The firm's platform combines swift analysis and ease of use with wide range of advanced analyses. The company was founded by Stig Morten Borch in February 2012 and is headquartered in Oslo, Norway. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
| IDOGEN AB (PUBL) | Biotechnology | Chief Executive Officer | |
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| CYXONE AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Medivir Personal AB | Corporate Officer/Principal | ||
| ZICCUM AB | Medical Specialties | Director/Board Member | |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Pharmaceuticals: Major | Director/Board Member | |
| Herder Consulting AB | Director/Board Member | ||
| Glycovisc BioTech AB | Corporate Officer/Principal | ||
| Theranostics Consulting SAS | Corporate Officer/Principal | ||
| SMO-CLINICA SAS | Founder | ||
| CODELAB CAPITAL | Packaged Software | Director of Finance/CFO | |
| ONCOZENGE AB | Pharmaceuticals: Major | Director/Board Member | |
| ELICERA THERAPEUTICS AB | Biotechnology | Director/Board Member | |
| University Pierre & Marie Curie | College/University | Doctorate Degree |
Statistik
International
| Norwegen | 20 |
| Schweden | 20 |
| Frankreich | 6 |
| Dänemark | 3 |
| Vereinigtes Königreich | 3 |
Sektoral
| Health Technology | 26 |
| Consumer Services | 10 |
| Commercial Services | 6 |
| Distribution Services | 3 |
| Process Industries | 2 |
Operativ
| Director/Board Member | 145 |
| Corporate Officer/Principal | 62 |
| Chairman | 35 |
| Independent Dir/Board Member | 27 |
| Chief Executive Officer | 26 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Flemming Ørnskov | 34 |
| Theresa Comiskey Olsen | 27 |
| Hilde Hermansen Steineger | 24 |
| Ann-Tove Kongsnes | 24 |
| William Castell | 22 |
| Hilde Furberg | 21 |
| Erling Øverland | 19 |
| Christina Elisabeth Herder | 15 |
| Kjell Göran Stenberg | 14 |
| Bernt Olav Røttingsnes | 13 |
| Jean-Claude Provost | 11 |
| Sharath Reddy | 11 |
| Kjetil Taskén | 11 |
| John Edminson | 11 |
| Aitana Peire | 9 |
- Börse
- Insiders
- Per Walday
- Unternehmensverbindungen
